Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.47 |
| ▸ | DRD4 | P21917 | 6/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | CCR3 | P51677 | 2/20 | 0.46 |
| ▸ | SMO | Q99835 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.44 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2957201 | 0.82 | SSTR5 (0.60) | — | |
| SCHEMBL2963856 | 0.80 | SSTR5 (0.52) | — | |
| SCHEMBL2957283 | 0.80 | SSTR5 (0.63) | KMT2AMCHR1DRD4SIGMAR1CCR3 | |
| SCHEMBL2964051 | 0.78 | KMT2A (0.58) | KMT2AMCHR1DRD4SIGMAR1CCR3 | |
| SCHEMBL2953675 | 0.77 | SSTR5 (0.51) | — | |
| SCHEMBL2953829 | 0.76 | MCHR1 (0.71) | MCHR1DRD4SIGMAR1 | |
| SCHEMBL4592061 | 0.76 | CSNK2A1 (0.48) | DRD4DRD2 | |
| SCHEMBL2954319 | 0.75 | MCHR1 (0.59) | MCHR1DRD4SIGMAR1SMO | |
| SCHEMBL2962114 | 0.75 | SSTR5 (0.65) | MCHR1DRD4 | |
| SCHEMBL2957956 | 0.74 | SSTR5 (0.61) | MCHR1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772253-B2 | Amide derivatives as somatostatin receptor 5 antagonists | HOFFMAN-LA ROCHE INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1893603-B1 | PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2009-10-14 | — | — | EP | disclosed |
| CN-101189226-A | Piperidin-4-yl-amide derivatives and their use as SST receptor subtype 5 antagonists | HOFFMANN LA ROCHE (CH) | 2008-05-28 | — | — | CN | disclosed |
| EP-1893603-A1 | PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006128803-A1 | PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-07 | — | — | WO | disclosed |
| US-20060276508-A1 | Amide derivatives as somatostatin receptor 5 antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276508-A1 | Amide derivatives as somatostatin receptor 5 antagonists | SSTR5, SSTR3, SSTR1 | KMT2A 3271/4885MCHR1 97/4885DRD4 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.